Above, a word cloud generated by ChatGPT 4o (openai.com) using input from RoosterBio-attributing publications’ abstracts and titles from 2024.

For those with limited experience in this arena, it might be tempting to caricature medical biotechnology research as a gladiatorial spectacle, a binary, “win/lose” showdown. Look at those rare “winners” of 2024 jostling for breakthroughs toward disease treatments and cures! Although competition for scarce grants, VC funding, and company budgets might seem dispiriting for some, RoosterBio wishes to shift perceptions away from this perspective. If there’s any contest at all, it’s no zero-sum game. Call it a win-win situation, collaboration, or simply cooperation. In this blog and previous ones, we’ve highlighted exemplars of our positive sum game as “RoosterPubs.” [1, 2, 3] These are the published science research articles, graduate theses, conference abstracts, pre-prints, reviews, application notes & “gray lit,” and book chapters that cite RoosterBio’s products and/or expertise.

Simply stated, we assert that the growing list of over 3,000 unique PIs, authors, bench scientists, technicians, and thought leaders from 2014 through 2024 benefitted. They approached RoosterBio’s solutions as a catalyst for their experimental workflows. Thus, in 2024 alone, more than 800 unique, individual authors were counted in more than 80 publishing venues, and of these, 514 were related to peer-reviewed scientific journal articles. Some were found in more than one article. This diverse group explored wide-ranging topics related to our core business to accelerate advanced cellular therapies and regenerative medicine toward the clinic. We, in turn, benefitted by learning new ways to assist our academic and commercial customers alike to solve new problems and, thereby, expand our repertoire of services and catalog offerings. That this list of authors accelerates across our history underscores RoosterBio’s successful “symbiotic” collaborations (Figure 1).

Figure 1, Chart showing annual totals of unique author names on science-related publications that provide attribution to RoosterBio products or expertise in the text. Blue bars: combined annual tally of unique authors found in peer-reviewed academic science journal articles. Orange bars: all authors, including those on reviews, pre-print articles, conference abstracts, graduate theses, news/application notes/gray lit, retractions (1), book chapters, and short reports.

Not only have more scientists invested in our bioprocess and cell culture solutions, but the resulting quantity of publications via their labors has also increased. In fact, we’re happy to note that 2024 was the most prolific year yet for “RoosterPubs” (Figure 2), either for peer-reviewed research articles or for other classes of non-patent literature (e.g., pre-prints, reviews, theses, conference abstracts, etc.). We speculated earlier that 2020-2021 were “outlier” years for our collaborators and customers due to COVID-19 lockdowns inspiring extra focus on writing and editing away from the benchtop; following this surge, there was a brief decline into 2022. Indeed, there was a similar retreat in publication tallies in the early-2020s observed across all PubMed entries. 2023 and 2024 saw RoosterPubs rebounding from this trend with exuberance. This remarkable achievement reflects the dedication and ingenuity of our research community while we reciprocate with commitment to support their groundbreaking work in 2025 and the years to come.

Figure 2, Stacked chart showing annual totals of science-related publications that provide attribution to RoosterBio in their text. Blue bars: peer-reviewed academic science journal articles. Orange bars: a combined annual tally of reviews, pre-print articles, conference abstracts, graduate theses, news/application notes/gray lit, retractions (1), book chapters, and short reports.

Our organization is keen on tracking where our research partners publish—both in formal, peer-reviewed research articles with data figures—as well as in review articles, pre-prints, posters, conference abstracts, white papers, theses, application notes, white papers, etc. (Figure 3, left). It can be beneficial to a young scientist’s career to exhibit a range of experiences on one’s CV with varied publishing media beyond the highly sought Cell, Science, or Nature paper. For RoosterBio, we’ve noted our presence in high-profile journals before. Nevertheless, we also carefully peruse the appearance of novel and innovative non-peer review content, since it can frequently signal the leading edge of a wave of new breakthroughs prior to formal publication. In 2024, we observed that a plurality of authors published only in our detectable list of peer-reviewed publications, while another 21% published in both peer-reviewed and non-peer-reviewed lit. About one-third published their work in only non-peer-reviewed material. This latter group adds up to a greater fraction than in years past, owing to more observable activity in pre-print research articles and in conference abstracts.

RoosterBio is also interested in scientist-authors who publish more than once with the assistance of our products, services, and expertise (Figure 3, right). In 2024, we found that 70% of the authors appeared in peer-reviewed research articles where we were mentioned for the very first time in an author’s text. However, in 30% of authors’ 2024 publications, they had already published with us previously (2014-2024).  We’re deeply grateful for the trust and confidence placed in us by both “first-time customers” as well as returning colleagues. Yet it’s notable that more than 30 of 2024’s authors appeared on five or more RoosterPubs. Of course, accolades belong solely to these leaders and their labs’ industriousness, but we’re “secretly” proud to help advance the state-of-the-art with our reliable bioprocessing platforms and deep knowledge base to develop primary cells and extracellular vesicles/EVs.

Figure 3 left, Pie chart showing that about 2/3 of the “RoosterPub” authors in 2024 were found in peer-reviewed publications. Right, about 30% of 2024’s authors on peer-reviewed research articles published in RoosterBio-citing articles more than once.

What did the authors explore in their research? In 2024 as in years past, RoosterBio’s mesenchymal stem/stromal cells (MSCs) have proved useful to tissue engineers and bioprinting experts (Figure 4), both on Earth [4] and even in low-earth orbit! [5] Of equal prominence is the category of “Cell Culture Bioprocess,” underscoring our effort to facilitate easier, hassle-free primary cell culture that is scalable from the benchtop to clinical applications such as “Cell Therapy” (shown as category). [6, 7] Up-and-coming research applications are reflected in our fast-growing category of “Exosome, EV, or Secretome Related,” which has witnessed massive growth across biomedicine as a prospective therapeutic, drug delivery, or diagnostic technology platform. [8, 9] In future years, we hope to see further kindling in publishing categories of gene therapy/gene editing as well as uses for our materials in vivo while en route to clinical translation, such as for “MSC 2.0” applications. [10, 11]

Figure 4, Inferred diversity of article content mined from abstract and/or title keywords. Some subject areas may overlap with others. Article sources for these data are peer-reviewed research articles that report the use of RoosterBio products and/or expertise within the text.

Academic and medical translational center research represents a smaller but profoundly important segment of RoosterBio’s business, the rest occupied by biotech industry players. We view this cadre of 3,000+ publishing investigators as the cutting edge of science, an incubator for both new talent and new entrepreneurship for the next generation. As RoosterBio is full of scientists, too, we understand and delight in others’ success, and marvel at each new step made possible by the proverbial mix of inspiration and perspiration and the instinct to do good. For this reason, we announce each year a group of “RoosterBio Development Awards,” whereby select recipients receive over $100K in combined products after completing a brief proposal. [12, 13, 14] Some such awardees have been gracious to present their ongoing work via our series of webinars, and the response has been overwhelmingly positive. [15, 16] We look forward to hosting many more such events in the coming months, so please stay tuned!

At the close of this blog, what could be more (in-?)appropriate than an ode to the 2024 authors on RoosterPubs? Apologies…We were too busy taking care of our customers to write it ourselves with sufficient time and effort, but we did have ChatGPT and SUNO handy to compose and arrange it for us. Perhaps file it under the “So Awful It’s Good” category? Good for a quick chuckle, maybe? Listen to it HERE, and behold ChatGPT’s lyrics in your honor…

Title: Publish & Flex

 

References

1. Candiello, Joe. RoosterBio Products Continue to Expand Presence in Major Mesenchymal Stem/Stromal Cell (MSC)-related Regenerative Medicine Peer Reviewed Publications. RoosterBio Blog 2018; Available from: https://www.roosterbio.com/blog/roosterbio-products-continue-to-expand-presence-in-major-mesenchymal-stem-stromal-cell-msc-related-regenerative-medicine-peer-reviewed-publications/.
2. Candiello, Joe. RoosterBio Products Continue to Support hMSC-Related Peer-Reviewed Publications in a Growing Number of Applications. RoosterBio Blog 2020; Available from: https://www.roosterbio.com/blog/roosterbio-products-continue-to-support-hmsc-related-peer-reviewed-publications-in-a-growing-number-of-applications/.
3. RoosterBio. “Holmes-work” & Scientific Publications Featuring RoosterBio: Authority of Evidence Before Evidence of Authority. RoosterBio Blog 2024; Available from: https://www.roosterbio.com/blog/holmes-work-scientific-publications-featuring-roosterbio-authority-of-evidence-before-evidence-of-authority/.
4. Ramos-Rodriguez, D. H., et al., Decellularized Extracellular Matrix Improves Mesenchymal Stromal Cell Spheroid Response to Chondrogenic Stimuli. Tissue Eng Part A, 2024. 10.1089/ten.tea.2024.0267
5. Klarmann, G. J., et al., 3D bioprinting meniscus tissue onboard the International Space Station. Life Sci Space Res (Amst), 2024. 43: p. 82-91. 10.1016/j.lssr.2024.09.004
6. Rowley, J., Boychyn, M., Kelly, T. Why Cell Manufacturing Matters: How Bioprocess Innovations Have Laid the Foundation for a Cell-Based Products Revolution. BioProcess International 2022; Available from: https://bioprocessintl.com/manufacturing/cell-therapies/why-cell-manufacturing-matters-how-bioprocess-innovations-have-laid-the-foundation-for-a-cell-based-products-revolution/.
7. Snyder, Jessica, Carson, Jonathan. The Story Behind the Media. RoosterBio Blog 2022; Available from: https://www.roosterbio.com/blog/the-story-behind-the-media/.
8. RoosterBio. Cytiva & RoosterBio’s Collaboration is Yielding Breakthroughs to Make Exosome Manufacture Easier from Benchtop to Bedside. RoosterBio Blog 2024; Available from: https://www.roosterbio.com/blog/cytiva-roosterbios-collaboration-is-yielding-breakthroughs-to-make-exosome-manufacture-easier-from-benchtop-to-bedside/.
9. RoosterBio. On the Exosome/Extracellular Vesicle Frontier, Choose Your Own Adventure. RoosterBio Blog 2023; Available from: https://www.roosterbio.com/blog/on-the-exosome-extracellular-vesicle-frontier-choose-your-own-adventure/.
10. Hildreth, Cade. MSCs: A Multi-Version Medicinal Technology System, Part I. BioInformant 2025; Available from: https://bioinformant.com/mscs-a-multi-version-medicinal-technology-system-part-i/.
11. Hildreth, Cade. A Multi-Version Medicinal Technology System, Part II. BioInformant 2025; Available from: https://bioinformant.com/a-multi-version-medicinal-technology-system-part-ii/.
12. RoosterBio. RoosterBio Inc. Announces Winners of 2020 hMSC Development Grants. 2021; Available from: https://www.prweb.com/releases/roosterbio-inc-announces-winners-of-2020-hmsc-development-grants-806684714.html.
13. RoosterBio. 2022 Development Award Winners. RoosterBio Blog 2022; Available from: https://www.roosterbio.com/press_release/roosterbio-2022-development-award/.
14. RoosterBio. Winners of RoosterBio’s 2024 Development Award. RoosterBio Blog 2024; Available from: https://www.roosterbio.com/blog/winners-of-roosterbios-2024-development-award/.
15. Bruno, Stefania. Anti-fibrotic Effects of Extracellular Vesicles Produced by MSCs Maintained in Chemically Defined Medium. 2024; Available from: https://tinyurl.com/yc2zdmph.
16. RoosterBio. Extracellular Vesicles (EVs) from Fully “Charged” MSCs Treat Advanced Cellular Models of Liver Fibrosis. RoosterBio Blog 2024; Available from: https://www.roosterbio.com/blog/extracellular-vesicles-evs-from-fully-charged-mscs-treat-advanced-cellular-models-of-liver-fibrosis/.